Table 5.
Table showing the studies using metronomic regimens in glioblastoma multiforme (GBM). CP, Cyclophosphamide; TMZ, Temozolomide.
| Author | Treatment | N | Patient type | SD | PR | ORR | TTP | PFS 6 | OS |
|---|---|---|---|---|---|---|---|---|---|
| Brandes, 2006 | TMZ 75 mg/ m2 days 1-21 q28d | 33 | Chemonaive, refractory to RT and/or surgery | - | - | 9% | - | 30.3% | - |
|
| |||||||||
| Kesari, 2007 | Etoposide 35 mg/ m2 days 1-21 CP 2 mg/kg days 22-42, Thalidomide Celecoxib |
48 | GBM and AG |
59% | 11% | - | - | 11 w (GBM) 14 w (AG) |
41.5 w (GBM) 42 w (AG) |
|
| |||||||||
| Balmaceda, 2008 | TMZ 200 mg/ m2 followed by 90 mg/m2 q12h 9 times |
120 | GBM, anaplastic astrocytoma, anaplastic oligodendroglioma |
- | - | - | - | 4.2 m 5.8 m 7.7 m |
8.8 m 14.6 m 18 m |
|
| |||||||||
| 1:21 | 1:GBM-refractory to conventional TMZ, | 1:17% | |||||||
| Perry, 2008 | TMZ 50 mg/ m2 qd | 2:14 | 2:GBM-refractory to conventional and adjuvant TMZ | - | - | - | - | 2:57% | - |
| 3:14 | 3:AG-refractory to conventional TMZ, | 3:42% | |||||||
|
| |||||||||
| Clarke, 2009 | TMZ 50 mg/ m2 qd | 43 | Pretreated with standard TMZ + RT | - | - | - | - | - | 15.1 m |
|
| |||||||||
| Reardon, 2009 | Bevacizumab 10 mg/kg two times a week | 59 | GBM and grade 3 glioma | - | - | - | - | 40.6% | 63.1 w |
| Etoposide 50 mg/ m2 qd days 1-21 q30d | 44.4% | 44.4 w | |||||||
|
| |||||||||
| Kong, 2010 | TMZ 40 mg/ m2 m2 qd or 50 mg/ m2qd | 38 | Pretreated GBM | - | - | - | - | 32.5% | 56.0% (6 m) |
|
| |||||||||
| Stockhammer, 2010 | TMZ 10 mg/ m2bid Celecoxib 200 mg |
28 | Pretreated GBM | - | - | - | 4.2 m | 43 % | - |
|
| |||||||||
| Verhoeff, 2010 | Bevacizumab 10 mg/kg q21d TMZ 50 mg/ m2 qd |
23 | High grade glioma | - | - | 20% | - | 17.4 % | 17.1 w |
|
| |||||||||
| Reardon, 2011 | Bevacizumab 10 mg/kg q14d With Etoposide 50 mg/ m2 days 1-21 q 30d or With TMZ 50 mg/ m2 m2 qd |
23 | Bevacizumab pretreated GBM, | 52% | - | - | - | 4.4% | - |
|
| |||||||||
| Omuro, 2013 | TMZ 50 mg/ m2 qd | 47 | Pretreated grade 3 malignant glioma and GBM | - | - | - | - | 19% | 7 m |
|
| |||||||||
| Zustovich, 2013 | TMZ 40 mg/ m2qd Sorafenib 400 mq qd |
43 | Pretreated GBM | - | - | - | - | 26% | 7.5 m |